Vicarious Surgical Inc Stock Price, News & Analysis

Vicarious Surgical Inc. (NYSE: RBOT, RBOT WS) announced it will release its financial results for the first quarter ended March 31, 2023, on May 8, 2023, after market close. The company will host a conference call at 4:30 p.m. Eastern Time to discuss these results. Vicarious Surgical is focused on advanced surgical robotics with the aim of enhancing surgical efficiency, improving patient outcomes, and reducing healthcare costs. Backed by prominent investors, including Bill Gates and Khosla Ventures, the company is known for its innovative approach that transports surgeons inside patients for minimally invasive surgeries. Stakeholders can access further information via the company's investor website.

Vicarious Surgical Inc. (NYSE: RBOT, RBOT WS) has announced its participation in two upcoming investor conferences. The company aims to enhance surgical procedures through innovative robotics technology.

The first event is the Cowen 43rd Annual Healthcare Conference, featuring a fireside chat on March 8th at 9:50 a.m. ET. The second is the Oppenheimer 33rd Annual Healthcare Conference, with a virtual presentation scheduled for March 14th at 1:20 p.m. ET. Live and archived versions of these presentations will be available on the company's website.

Vicarious Surgical reported a cash burn of $67 million for 2022, meeting its objective, and announced initiatives to extend its cash runway. The company expects 2023 cash burn between $55-$65 million. Vicarious Surgical's operating expenses surged to $80.1 million in 2022 versus $38.2 million in 2021, with an adjusted net loss of $78.8 million, or $0.65 per share. Despite a GAAP net income of $5.2 million for the year, the company reported significant losses. Notable achievements include the completion of the Beta 2 robotic system and partnerships with major healthcare providers, enhancing its market position.

Vicarious Surgical Inc. (NYSE: RBOT, RBOT WS) will report its financial results for the fourth quarter and full year ended December 31, 2022, after market close on February 13, 2023. A conference call will follow at 4:30 p.m. ET for management to discuss the results. Investors can join by calling +1 (646) 904 5544 domestically or +1 (929) 526 1599 internationally. The company develops advanced surgical robotics aimed at improving the efficiency of procedures and reducing costs, using proprietary technology to perform minimally invasive surgeries.

Vicarious Surgical Inc. (NYSE:RBOT) has appointed Dr. Victoria Carr-Brendel to its Board of Directors as of January 23, 2023. Dr. Carr-Brendel brings over 24 years of experience in medical device development and leadership roles, including her current position at Sonova Group. Her expertise is expected to enhance the company's efforts in bringing innovative surgical solutions to market. The announcement also includes the resignation of Phil Liang, a technology-focused venture capitalist. The company aims to improve surgical procedures' efficiency, outcomes, and costs through its unique robotic systems.

Vicarious Surgical Inc. (NYSE:RBOT) demonstrated its Beta 2 surgical robotic platform on December 6, 2022, highlighting advancements in technology and successful cadaveric testing. CEO Adam Sachs emphasized the importance of this milestone, while surgeon Dr. Igor Belyansky showcased the system’s innovative capabilities in a recent procedure. Collaborating with University Hospitals, the company aims to improve minimally invasive surgery outcomes. Vicarious Surgical leads in developing robotic technology to enhance surgical efficiency and patient care.

Vicarious Surgical (NYSE:RBOT) announced the successful use of its Beta 2 prototype for cadaveric ventral hernia repairs by renowned surgeon Igor Belyansky. This milestone, showcasing advanced robotic surgical capabilities, is set to be highlighted on December 6, 2022, during Vicarious Surgical's Beta 2 Demonstration Day. The prototype aims to improve surgical efficiency and patient outcomes through minimally invasive techniques using a single-port approach. The collaboration with Belyansky underscores the company's commitment to innovation in robotic surgery.

Vicarious Surgical Inc. (NYSE: RBOT, RBOT WS) will participate in two upcoming investor conferences. The company, specializing in next-generation robotics to enhance surgical procedures, will host a virtual fireside chat at the 5th Annual Evercore ISI HealthCONx Conference on November 29 at 3:05 p.m. ET, followed by another chat at the 34th Annual Piper Sandler Healthcare Conference on November 30 at 1:00 p.m. ET. Interested investors can access the presentations live or archived via the company's website.

Vicarious Surgical Inc. (NYSE: RBOT, RBOT WS) announces that its robotic system has been included in TIME's Best Inventions of 2022, recognized for its innovative design. The system utilizes one camera and two multi-jointed arms for minimally invasive surgeries, demonstrating a full replication of the surgeon's movements. The company completed its Beta 2 system design earlier this year and plans to showcase it on December 6, 2022. The technology has received FDA Breakthrough Device Designation, aiming to enhance surgical efficiency while reducing healthcare costs.